Discover our high-purity APIs and plant-derived nutritional precursors.
The global pharmaceutical supply chain is currently undergoing a radical transformation. As the demand for personalized medicine and complex small-molecule drugs rises, the role of Active Pharmaceutical Ingredients (APIs) and Chemical Intermediates has shifted from mere commodities to strategic assets. In 2024, the global API market is projected to exceed USD 200 billion, driven by an aging global population, the surge in chronic diseases, and a massive pivot toward bio-fermentation and green chemistry.
Supply chain resilience is no longer an option but a necessity. Leading pharmaceutical enterprises in North America, Europe, and the APAC region are increasingly seeking partners who offer more than just raw materials; they demand Information Gain—deep technical insights into metabolic pathways, stability profiles, and regulatory compliance (FDA, EMA, NMPA).
Meeting the surge in oncology and autoimmune treatments with precise molecular synthesis and containment technologies.
Implementing atom-efficient reactions to reduce environmental impact while maintaining high yields in intermediate production.
Utilizing computational chemistry to predict reaction outcomes and optimize the synthesis of novel chemical entities (NCEs).
Jiangxi Serum Pharma Industries Co., Ltd. is a professional supplier of pharmaceutical and nutritional products in China. For nearly 10 years, we have been dedicated to exporting biological products, vaccines, Western medicines, raw materials, intermediates, medical consumables, food additives, and plant extracts, and have accumulated rich industry experience.
Our pharmaceutical products consist of biological products, vaccines, western medicines, raw material, intermediates, medical consumables, with high quality and affordable prices. Serum Pharma will continuously monitor the development of the cutting-edge markets.
China remains the powerhouse of global API production, accounting for a significant portion of the world's generic and innovative drug precursors. The efficiency advantage stems not just from scale, but from industrial integration. In pharmaceutical hubs like Jiangxi, we leverage a comprehensive ecosystem that includes:
Advancing beyond supply to provide high-value technical customization.
Optimized ingredient blending for immediate manufacturing integration, ensuring homogeneity and consistency in dosages.
Enhancing the bioavailability and stability of poorly soluble APIs through advanced crystalline engineering and molecular arrangement.
Leveraging microbial synthesis to produce complex molecules, peptides, and proteins with higher purity and lower chemical waste.
The application of our APIs and Intermediates spans various high-growth sectors, each requiring specific technical handling:
Production of high-purity NMN (Nicotinamide Mononucleotide) and Coenzyme Q10 for the burgeoning global wellness and longevity supplement market.
Utilizing Pea and Mung Bean Peptides in water-soluble formulations for high-performance sports nutrition and medical foods (FSMP).
Critical API molecules like Dexamethasone Sodium Phosphate for inflammatory treatments and life-saving biological vaccines.
The industry is moving toward "Integrated CDMO Services." Buyers are no longer looking for just a vendor; they seek a partner capable of handling the entire lifecycle. Key trends include:
1. Continuous Manufacturing: Shifting away from batch processing to continuous flow chemistry to improve quality control and reduce the footprint of API manufacturing.
2. Oral GLP-1 Breakthroughs: As mentioned in recent breakthroughs, the shift from injectable peptides to oral small-molecule GLP-1 drugs (like orforglipron) is creating massive new demand for specific synthetic intermediates.
3. Plant-Derived Alternatives: The rise of plant-derived Squalene and botanical extracts highlights a shift toward vegan-friendly and sustainable pharmaceutical precursors.
Procuring APIs requires a multi-layered verification process. Global enterprises must focus on TCO (Total Cost of Ownership) rather than just the price per kilo. Factors include logistics reliability, cold-chain capabilities for biologicals, and the transparency of the Quality Management System (QMS).
At Serum Pharma, we facilitate this by providing full documentation (COA, MSDS, GMP certificates) and maintaining a robust audit trail, ensuring that our 500+ global partners can source with confidence and minimize regulatory risk.
Exploring the shift toward sustainable sources in the pharmaceutical and cosmetic sectors.
An in-depth look at this essential molecule's role in modern emergency medicine.
Analysis of Lilly's oral small-molecule GLP1 drug approval and its impact on the peptide supply chain.
High-quality pharmaceutical grade oils and advanced nutritional supplements.
